Harbour BioMed (2142.HK) announced that it has entered into a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb. The partnership aims to discover and develop next-generation multi-specific antibodies.
Under the terms of the agreement, Harbour BioMed will work closely with Bristol Myers Squibb to advance and accelerate multi-specific antibody discovery programs. In exchange, Harbour BioMed is eligible to receive payments totaling $90 million, along with additional development and commercial milestone payments of up to $1.035 billion. The agreement also includes tiered royalties, should Bristol Myers Squibb choose to advance all potential programs.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.